使用同步18F-FDG-PET/MRI多参数评估鉴别胶质瘤复发与治疗所致坏死:单机构回顾性研究
本研究纳入35例治疗后胶质瘤患者共41个强化病灶,采用同步FDG-PET/MRI计算rCBVmean、ADCmean、Cho/Cr及最大和平均靶本比,以组织病理学或临床影像随访为标准,评估各参数单独及联合诊断胶质瘤复发的效能。多变量ROC分析显示,MRI参数(ADCmean和Cho/Cr)联合PET参数(平均靶本比)的AUC达0.935±0.046,较三者MRI参数联合的AUC 0.913±0.053有所提高。
要点
- Cho/Cr单独诊断复发准确率90.9%,高于rCBVmean的77.5%和ADCmean的78.0%。
- MRI参数(ADCmean和Cho/Cr)联合PET平均靶本比的AUC为0.935±0.046,显示诊断准确性提高。
- 同步FDG-PET/MRI可提供相关且协同的多参数评估,具有更高的准确性和临床实用性。
核心结论
- 同步FDG-PET/MRI多参数评估胶质瘤复发具有更高的准确性和临床实用性,MRI参数联合PET参数可进一步提高诊断准确性。
研究设计与样本
- 单机构回顾性研究;35例治疗后胶质瘤患者共41个强化病灶(WHO II级9个、III级13个、IV级19个);采用同步FDG-PET/MRI计算rCBVmean、ADCmean、Cho/Cr及最大和平均靶本比;以组织病理学或临床影像随访为标准。
诊断标准与关键数值
- rCBVmean诊断复发准确率77.5%;ADCmean准确率78.0%;Cho/Cr准确率90.9%;最大靶本比准确率87.8%;平均靶本比准确率87.8%;3个MRI参数联合AUC 0.913±0.053;MRI参数(ADCmean和Cho/Cr)联合PET平均靶本比AUC 0.935±0.046。
临床应用与阅片要点
- 同步FDG-PET/MRI可提供相关且协同的多参数评估,具有更高的准确性和临床实用性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Differentiating glioma recurrence from treatment-induced necrosis can be a challenge on conventional imaging. This study aimed to assess the diagnostic performance of each functional MR imaging and PET parameter derived by using simultaneous FDG-PET/MR imaging individually and in combination in the evaluation of suspected glioma recurrence.
MATERIALS AND METHODS: Thirty-five treated glioma patients with 41 enhancing lesions (World Health Organization grade II = 9, III = 13, IV = 19) on MR imaging after an operation followed by radiation therapy and/or chemotherapy formed part of this study. Using PET/MR imaging, we calculated the normalized mean relative CBV, mean ADC, Cho/Cr, and maximum and mean target-to-background ratios. Statistical analysis was performed to determine the diagnostic performance of each parameter by receiver operating characteristic analysis individually and in combination with multivariate receiver operating characteristic analysis for the detection of glioma recurrence. Histopathology or clinicoradiologic follow-up was considered the criterion standard.
RESULTS: Of 35 patients, 25 (30 lesions) were classified as having a recurrence and 10 (11 lesions) patients as having treatment-induced necrosis. Parameters like rCBVmean (mean relative CBV), ADCmean, Cho/Cr, and maximum and mean target-to-background ratios were statistically significant in the detection of recurrent lesions with an accuracy of 77.5%, 78.0%, 90.9%, 87.8%, and 87.8%, respectively. On multivariate receiver operating characteristic analysis, the combination of all 3 MR imaging parameters resulted in an area under the curve of 0.913 ± 0.053. Furthermore, an area under the curve of 0.935 ± 0.046 was obtained when MR imaging parameters (ADCmean and Cho/Cr) were combined with the PET parameter (mean target-to-background ratio), demonstrating an increase in diagnostic accuracy.
CONCLUSIONS: Simultaneous PET/MR imaging with FDG offers correlative and synergistic multiparametric assessment of glioma recurrence with increased accuracy and clinical utility.
引用
- Jena A, Taneja S, Jha A, et al. Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous 18F-FDG-PET/MRI: A Single-Institution Retrospective Study. AJNR Am J Neuroradiol. 2017. PMID: 28341716. doi:10.3174/ajnr.A5124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。